Physician profile
Patricia Cline
NPI 1992861900
$5,721.07
in general payments reported to CMS, 2019-2025
47 companies · $910 in 2025
The $910 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $566 · 2021: $541 · 2022: $909 · 2023: $1,391 · 2024: $837 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.47 |
| Education | $213.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $769.59 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $595.64 | 2019-2025 | Lo Loestrin Fe, Liletta |
| Bayer Healthcare Pharmaceuticals INC. | $555.77 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $380.31 | 2022-2025 | |
| Biogen, INC. | $313.03 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $271.78 | 2020-2024 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Amgen INC. | $262.70 | 2019-2024 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $243.02 | 2023-2025 | Myfembree |
| Organon LLC | $212.50 | 2021-2025 | Jada System, Nexplanon |
| Therapeuticsmd, INC. | $155.71 | 2019-2022 | |
| Radius Health, INC. | $147.54 | 2024-2025 | Tymlos |
| Shield Therapeutics INC | $145.28 | 2023 | Accrufer |
| Caldera Medical, INC | $144.60 | 2021-2023 | Desara |
| Pfizer INC. | $141.57 | 2020-2024 | |
| Revvity, INC. | $121.07 | 2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.